vs
Klaviyo, Inc.（KVYO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Klaviyo, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.7倍（$350.2M vs $207.3M），Klaviyo, Inc.净利率更高（2.0% vs -62.0%，领先64.0%），Klaviyo, Inc.同比增速更快（29.6% vs 25.9%），Klaviyo, Inc.自由现金流更多（$90.7M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 29.1%）
Klaviyo是一家美国科技企业，专注于提供营销自动化平台服务，核心应用场景涵盖邮件营销与短信营销，能够帮助不同规模的品牌商家高效触达用户，提升营销转化效果，现已服务全球众多电商及零售领域客户。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
KVYO vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $350.2M | $207.3M |
| 净利润 | $7.0M | $-128.6M |
| 毛利率 | 72.2% | — |
| 营业利润率 | -0.5% | -54.7% |
| 净利率 | 2.0% | -62.0% |
| 营收同比 | 29.6% | 25.9% |
| 净利润同比 | 126.1% | 3.5% |
| 每股收益（稀释后） | $0.03 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $350.2M | $207.3M | ||
| Q3 25 | $310.9M | $159.9M | ||
| Q2 25 | $293.1M | $166.5M | ||
| Q1 25 | $279.8M | $139.3M | ||
| Q4 24 | $270.2M | $164.6M | ||
| Q3 24 | $235.1M | $139.5M | ||
| Q2 24 | $222.2M | $147.0M | ||
| Q1 24 | $210.0M | $108.8M |
| Q4 25 | $7.0M | $-128.6M | ||
| Q3 25 | $-426.0K | $-180.4M | ||
| Q2 25 | $-24.3M | $-115.0M | ||
| Q1 25 | $-14.1M | $-151.1M | ||
| Q4 24 | $-27.0M | $-133.2M | ||
| Q3 24 | $-1.3M | $-133.5M | ||
| Q2 24 | $-4.9M | $-131.6M | ||
| Q1 24 | $-12.9M | $-170.7M |
| Q4 25 | 72.2% | — | ||
| Q3 25 | 75.5% | — | ||
| Q2 25 | 75.7% | — | ||
| Q1 25 | 75.8% | — | ||
| Q4 24 | 73.4% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 78.6% | — |
| Q4 25 | -0.5% | -54.7% | ||
| Q3 25 | -3.5% | -106.9% | ||
| Q2 25 | -10.7% | -64.8% | ||
| Q1 25 | -8.5% | -102.6% | ||
| Q4 24 | -12.8% | -74.3% | ||
| Q3 24 | -5.6% | -94.6% | ||
| Q2 24 | -6.3% | -79.1% | ||
| Q1 24 | -10.5% | -151.9% |
| Q4 25 | 2.0% | -62.0% | ||
| Q3 25 | -0.1% | -112.8% | ||
| Q2 25 | -8.3% | -69.0% | ||
| Q1 25 | -5.0% | -108.5% | ||
| Q4 24 | -10.0% | -80.9% | ||
| Q3 24 | -0.6% | -95.7% | ||
| Q2 24 | -2.2% | -89.5% | ||
| Q1 24 | -6.1% | -156.8% |
| Q4 25 | $0.03 | $-1.28 | ||
| Q3 25 | $0.00 | $-1.81 | ||
| Q2 25 | $-0.09 | $-1.17 | ||
| Q1 25 | $-0.05 | $-1.57 | ||
| Q4 24 | $-0.09 | $-1.34 | ||
| Q3 24 | $-0.01 | $-1.40 | ||
| Q2 24 | $-0.02 | $-1.52 | ||
| Q1 24 | $-0.05 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $1.6B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $1.1B | $421.0M | ||
| Q3 25 | $980.3M | $202.5M | ||
| Q2 25 | $935.5M | $176.3M | ||
| Q1 25 | $888.4M | $127.1M | ||
| Q4 24 | $881.5M | $174.0M | ||
| Q3 24 | $826.7M | $150.6M | ||
| Q2 24 | $793.6M | $480.7M | ||
| Q1 24 | $755.8M | $112.3M |
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.1B | $9.2M | ||
| Q2 25 | $1.1B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.0B | $255.0M | ||
| Q3 24 | $1.0B | $346.8M | ||
| Q2 24 | $979.5M | $432.4M | ||
| Q1 24 | $937.5M | $140.3M |
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.4B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.1B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $90.7M | $-100.8M |
| 自由现金流率自由现金流/营收 | 25.9% | -48.6% |
| 资本支出强度资本支出/营收 | 0.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 13.26× | — |
| 过去12个月自由现金流最近4个季度 | $208.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $93.2M | $-99.8M | ||
| Q3 25 | $54.8M | $-91.4M | ||
| Q2 25 | $55.7M | $-108.3M | ||
| Q1 25 | $14.4M | $-166.5M | ||
| Q4 24 | $60.1M | $-79.3M | ||
| Q3 24 | $38.8M | $-67.0M | ||
| Q2 24 | $40.9M | $-77.0M | ||
| Q1 24 | $26.2M | $-190.7M |
| Q4 25 | $90.7M | $-100.8M | ||
| Q3 25 | $52.5M | $-92.7M | ||
| Q2 25 | $53.7M | $-110.7M | ||
| Q1 25 | $11.7M | $-167.8M | ||
| Q4 24 | $57.7M | $-79.5M | ||
| Q3 24 | $37.2M | $-68.6M | ||
| Q2 24 | $40.1M | $-79.0M | ||
| Q1 24 | $24.9M | $-193.9M |
| Q4 25 | 25.9% | -48.6% | ||
| Q3 25 | 16.9% | -58.0% | ||
| Q2 25 | 18.3% | -66.5% | ||
| Q1 25 | 4.2% | -120.5% | ||
| Q4 24 | 21.4% | -48.3% | ||
| Q3 24 | 15.8% | -49.2% | ||
| Q2 24 | 18.1% | -53.7% | ||
| Q1 24 | 11.9% | -178.2% |
| Q4 25 | 0.7% | 0.5% | ||
| Q3 25 | 0.7% | 0.8% | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 1.0% | 1.0% | ||
| Q4 24 | 0.9% | 0.1% | ||
| Q3 24 | 0.7% | 1.2% | ||
| Q2 24 | 0.3% | 1.4% | ||
| Q1 24 | 0.6% | 3.0% |
| Q4 25 | 13.26× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KVYO
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
